Otsuka (OTCMKTS:OTSKY) Upgraded by Zacks Research to “Hold” Rating

Otsuka (OTCMKTS:OTSKY) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

A number of other research analysts have also commented on OTSKY. The Goldman Sachs Group lowered shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. Morgan Stanley upgraded Otsuka to an “overweight” rating in a research report on Friday, January 23rd. Finally, UBS Group raised Otsuka to a “hold” rating in a research note on Tuesday, January 27th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Otsuka currently has a consensus rating of “Hold”.

Otsuka Stock Performance

Shares of Otsuka stock opened at $36.39 on Tuesday. The firm’s fifty day simple moving average is $32.73 and its 200-day simple moving average is $29.65. Otsuka has a 12 month low of $21.64 and a 12 month high of $36.55. The stock has a market capitalization of $39.09 billion and a price-to-earnings ratio of 15.82. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.